HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.

Abstract
MDL 26479 is a new drug undergoing clinical evaluation for the treatment of depression and for memory loss associated with Alzheimer's disease. As part of a dose tolerance trial, the single- (SD) and multiple-dose (MD) pharmacokinetics of MDL 26479 were evaluated in healthy male volunteers. SDs ranging from 2 to 465 mg, and doses of 30, 60, and 120 mg administered twice daily for 28 d, were examined. Serial blood samples were collected for up to 48 h. Plasma MDL 26479 concentrations were determined by HPLC. Plasma MDL 26479 concentration versus time profiles increased rapidly, followed by multiexponential decline. Time to maximum plasma concentration increased over the 230-fold SD range from 0.5 to 3.8 h. Maximum concentrations and areas under the concentration versus time curves increased disproportionately with dose. Apparent oral clearance estimates decreased from 52.9 to 13.8 Lh-1. MD pharmacokinetic parameters for doses from 30 to 120 mg were consistent with those observed following SD, thus indicating that SD pharmacokinetics are predictive of MD. SD and MD terminal half-life estimates were similar and independent of dose.
AuthorsD K Robbins, S J Hutcheson, T D Miller, V I Green, V O Bhargava, S J Weir
JournalBiopharmaceutics & drug disposition (Biopharm Drug Dispos) Vol. 18 Issue 4 Pg. 325-34 (May 1997) ISSN: 0142-2782 [Print] England
PMID9158880 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antidepressive Agents
  • GABA-A Receptor Agonists
  • Triazoles
  • suritozole
Topics
  • Administration, Oral
  • Adult
  • Antidepressive Agents (administration & dosage, pharmacokinetics)
  • Dose-Response Relationship, Drug
  • GABA-A Receptor Agonists
  • Humans
  • Male
  • Middle Aged
  • Reference Values
  • Triazoles (administration & dosage, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: